EUVIMEDObjevte EUVIMED
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Open access · CC BY 4.0

Extended‐release buprenorphine treatment for opioid use disorder: A mixed‐methods study of response and experience

Natalie Lowry iD, Andrew McKechnie, Edward Day, Eilish Gilvarry, Fiona Cowden, Rachel Evans, Rosie Locke, Robbie Murray, Rob Vanderwaal, Stacey Johnstone, Zoe Hoare, Michael Kelleher and 2 more

Addiction · 2025-10 · 120 (10) · 2055-2066

DOI: 10.1111/add.70106 ↗

At a glance

Randomisierte kontrollierte Studie in Addiction, published online on 2025-06-20. Written by Natalie Lowry and 13 co-authors. Institution: Addictions Department, School of Academic Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. Major MEDLINE topics: Buprenorphine, Opioid-Related Disorders, Opiate Substitution Treatment, Narcotic Antagonists. Cited 4 times so far (Crossref); 45 references. The full text is freely available (open access, CC BY 4.0). Funded by: Indivior UK Limited.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background and aims An investigation of 24 weeks of extended‐release buprenorphine (BUP‐XR; Sublocade®) treatment for adults with opioid use disorder (OUD). Study aims were to characterise variations in clinical response, investigate personal factors influencing BUP‐XR experience and identify opportunities to tailor treatment interventions.

Design

A convergent parallel mixed‐methods evaluation embedded in a five‐centre, phase 3, randomised controlled trial of BUP‐XR versus daily oral methadone or sublingual buprenorphine.

Setting

Four of five National Health Service addictions treatment clinics in England and Scotland from the trial.

Participants

Participants were recruited after they completed the 24‐week endpoint. Forty‐nine participants (31%) from the trial completed the qualitative interview.

Measurements

Three outcome measures from the trial's dataset were used descriptively: (1) fortnightly clinic visit administered TimeLine Follow‐Back interview and urine drug screen data on use of non‐medical opioids, cocaine and benzodiazepines; (2) the frequency version of the 11‐item Craving Experience Questionnaire administered at baseline and endpoint; and (3) the Structured Clinical Interview for DSM‐5 disorders for diagnosis of early OUD and cocaine use disorder (CUD) remission. Data visualisation (by heatmap) identified drug use response sub‐groups. A topic‐guided, semi‐structured qualitative interview was analysed by Interactive Categorisation.

Findings

Three response sub‐groups were identified: Group 1 [14 (28.5%) of 49 participants] had the highest level of response, characterised by continuous abstinence from opioids, cocaine and benzodiazepines, improvements in craving control and mental and physical health in the majority, and a high level of remission and satisfaction with care; Group 2 [14 (28.5%) of 49 participants] had the next level of response, characterised by continuous abstinence from opioids, but some with opioid craving and some with compensatory use of cocaine and benzodiazepine to cope with anxiety and stress; Group 3 [21 (43.0%) of 49 participants] were not continuously abstinent from opioids during follow‐up, the majority had dual OUD and CUD at trial enrolment, some reported breakthrough opioid withdrawal symptoms during follow‐up, the majority reported improvements in mental health, but many reported opioid and cocaine cravings and compensatory use of cocaine and benzodiazepines.

Conclusions

There appears to be variation in response and experience of extended‐release buprenorphine during the first six months of treatment, depending on substance use and physical health. This highlights the need for tailored treatment plans based on differing individual needs.

Subjects

MeSH terms (MEDLINE)

BuprenorphineOpioid-Related DisordersOpiate Substitution TreatmentNarcotic AntagonistsHumansMaleAdultFemaleDelayed-Action PreparationsMiddle AgedTreatment OutcomeMethadoneEnglandScotlandCravingCocaine-Related DisordersAdministration, Sublingual

Author keywords

extended‐release buprenorphinelong‐acting injectable buprenorphinemixed‐methodsopioid use disorderpatient experiencequalitative evaluation

Substances

BuprenorphineDelayed-Action PreparationsNarcotic AntagonistsMethadone

Authors and institutions

  • Addictions Department, School of Academic Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
  • Lambeth Drug and Alcohol Service, South London and Maudsley NHS Foundation Trust, London, UK.
  • Dundee Drug and Alcohol Recovery Service, Dundee Health and Social Care Partnership, Scotland, UK.
  • Solihull Integrated Addiction Service, Birmingham and Solihull Mental Health NHS Foundation Trust, Birmingham, UK.
  • Institute for Mental Health, School of Psychology, Birmingham University, Birmingham.
  • Newcastle Treatment and Recovery, Cumbria, Northumberland, Tyne and Wear NHS Foundation, Newcastle Upon Tyne, UK.

ORCID profiles: Natalie Lowry, John Marsden

Funding

  • Indivior UK Limited

Cite

APA

Lowry, N., McKechnie, A., Day, E., Gilvarry, E., Cowden, F., Evans, R., Locke, R., Murray, R., Vanderwaal, R., Johnstone, S., Hoare, Z., Kelleher, M., Mitcheson, L., & Marsden, J. (2025). Extended‐release buprenorphine treatment for opioid use disorder: A mixed‐methods study of response and experience. Addiction, 120(10), 2055-2066. https://doi.org/10.1111/add.70106

Vancouver

Lowry N, McKechnie A, Day E, Gilvarry E, Cowden F, Evans R, et al. Extended‐release buprenorphine treatment for opioid use disorder: A mixed‐methods study of response and experience. Addiction. 2025;120(10):2055-2066. doi:10.1111/add.70106

BibTeX
@article{Lowry2025,
  author = {Lowry, Natalie and McKechnie, Andrew and Day, Edward and Gilvarry, Eilish and Cowden, Fiona and Evans, Rachel and Locke, Rosie and Murray, Robbie and Vanderwaal, Rob and Johnstone, Stacey and Hoare, Zoe and Kelleher, Michael and Mitcheson, Luke and Marsden, John},
  title = {Extended‐release buprenorphine treatment for opioid use disorder: A mixed‐methods study of response and experience},
  journal = {Addiction},
  year = {2025},
  volume = {120},
  number = {10},
  pages = {2055--2066},
  doi = {10.1111/add.70106}
}
Start for free →